Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNV2197944 in Diabetic Peripheral Neuropathy
NCT01893125Phase 2Completed
- Sponsor
- Convergence Pharmaceuticals
- Start
- Aug 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CNV-2197944 in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by Convergence Pharmaceuticals. Primary endpoint: Pain Intensity Numerical Rating Scale at 21 days. Started Aug 2013; status: completed.
02
Drugs
CNV-2197944
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01893125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893125.